{"id":57,"date":"2018-12-17T23:47:44","date_gmt":"2018-12-17T23:47:44","guid":{"rendered":"http:\/\/www.hepbunited.org\/blog\/?p=57"},"modified":"2018-12-17T23:47:44","modified_gmt":"2018-12-17T23:47:44","slug":"webinar-hepatitis-delta-current-and-future-treatments","status":"publish","type":"post","link":"https:\/\/www.hepbunited.org\/blog\/webinar-hepatitis-delta-current-and-future-treatments\/","title":{"rendered":"Webinar: Hepatitis Delta &#8211; Current and Future Treatments"},"content":{"rendered":"<p style=\"text-align: center;\"><strong>Join us for a Webinar: Hepatitis Delta: Current and Future Treatments<\/strong><br \/>\n<strong>Tuesday, January 8th 2019<\/strong><br \/>\n<strong>7:00 AM PT \/ 10:00 AM ET<\/strong><\/p>\n<p>While scientific advancements in the last 20 years have brought highly effective treatment options for hepatitis B patients; treatments for hepatitis B and delta coinfected patients have lagged behind. Interferon therapy remains the only somewhat effective treatment option for 15-20 million patients who are anxiously awaiting new drugs to control their coinfection. With 7 new drugs in clinical trials, there is hope.<\/p>\n<p>Join professor Cihan Yurdaydin, MD, secretary general for the World\u00a0Gastroenterology Organization and Educational Councilor of EASL, for an in-depth perspective on current treatment regimens for hepatitis delta and a look at new drugs in the pipeline that show promise for more effective future treatments.<\/p>\n<p><strong>Register\u00a0<a href=\"https:\/\/register.gotowebinar.com\/register\/4268838896018869506\" target=\"_blank\" rel=\"noopener\">here\u00a0<\/a><\/strong>&#8211;\u00a0even if you cannot attend live, please register and we will email you the webinar recording!<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Join us for a Webinar: Hepatitis Delta: Current and Future Treatments Tuesday, January 8th 2019 7:00 AM PT \/ 10:00 AM ET While scientific advancements in the last 20 years have brought highly effective treatment options for hepatitis B patients; treatments for hepatitis B and delta coinfected patients have lagged behind. Interferon therapy remains the &hellip; <\/p>\n<p><a href=\"https:\/\/www.hepbunited.org\/blog\/webinar-hepatitis-delta-current-and-future-treatments\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Webinar: Hepatitis Delta &#8211; Current and Future Treatments<\/span> &rarr;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/57"}],"collection":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/comments?post=57"}],"version-history":[{"count":1,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/57\/revisions"}],"predecessor-version":[{"id":58,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/57\/revisions\/58"}],"wp:attachment":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/media?parent=57"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/categories?post=57"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/tags?post=57"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}